MILAN, ITALY — Amplifon has announced the successful placement of €600 million (~$690 million USD) in bonds, securing additional financing for its planned acquisition of GN Hearing’s hearing aid business.
The five-year bond offering, which matures in 2031, attracted substantial interest from European institutional investors. According to Amplifon, demand at its peak exceeded five times the amount of bonds offered.
The financing represents another step toward completing the acquisition of GN Hearing, announced in March 2026. The transaction, valued at approximately $2.5 billion when announced, would bring together one of the world’s largest hearing care retail networks with a major global hearing aid manufacturer.
Financing the GN Hearing Acquisition
Amplifon said proceeds from the bond offering will be used alongside €900 million (~$1.04 billion USD) in bank financing and existing cash resources, including proceeds from an equity offering completed in May, to fund the cash portion of the GN Hearing acquisition and refinance existing debt.
Part of the proceeds will also be used to repay €350 million (~$403 million USD) in bonds originally issued in 2020 and scheduled to mature in February 2027.
The new bonds carry a fixed annual interest rate of 4.875% and are scheduled to mature in five years. They will be listed on the Luxembourg Stock Exchange and offered to institutional investors outside the United States.
The latest financing follows a €1.35 billion loan agreement announced in June, which was arranged to support the acquisition’s cash component. The new bond offering forms part of Amplifon’s broader financing strategy as it prepares to complete the transaction.
Amplifon CEO Enrico Vita said the successful offering provides greater financial certainty as the company prepares for the acquisition.
“The successful placement of our bond, backed by strong demand from leading institutional investors, reflects the market’s confidence in Amplifon’s strategy. This transaction, together with our new bank facilities, allows us to complete the financing structure for the GN Hearing acquisition and, at the same time, refinance the notes issued in 2020, extending our average debt maturity. This allows us to fully focus on integration of GN Hearing and on delivering sustainable value for all our stakeholders,” said Vita.
Acquisition Moves Closer to Completion
The bond placement follows several significant developments in the acquisition process over the past several months.
Under the agreement announced in March, Amplifon will acquire GN’s Hearing business, including established hearing aid brands such as ReSound, Beltone, and Interton. The transaction includes approximately €1.69 billion in cash and 56 million newly issued Amplifon shares.
In September, Amplifon outlined plans to issue the new shares to GN, an important component of the transaction’s financing structure. Shareholders subsequently approved the capital increase on October 29, removing another significant obstacle to completion.
The acquisition also remains a central focus of Amplifon’s business strategy. In its third-quarter 2026 financial results, the company reported improving profitability and confirmed that preparations for integrating GN Hearing were progressing according to schedule.
Most recently, on November 6, GN Store Nord and Amplifon announced that all required regulatory approvals had been secured, including clearance from the European Commission. The companies continue to expect the transaction to close by the end of 2026.
Although regulatory approval and financing arrangements are now in place, the acquisition itself has not yet been finalized. The companies must still complete the remaining separation and closing activities before ownership of GN Hearing can formally transfer to Amplifon.
What the Transaction Means for Hearing Healthcare
The acquisition would represent a significant development for the hearing healthcare industry, combining Amplifon’s extensive global hearing care retail operations with GN Hearing’s manufacturing, research, and hearing technology businesses.
GN Hearing develops and manufactures hearing aids and related technology through brands including ReSound, Beltone, Interton, Danavox, and Danalogic. Amplifon, meanwhile, operates a large international network of hearing care clinics and retail locations.
Combining these operations would give Amplifon greater direct involvement in hearing aid research, development, and manufacturing, alongside its existing clinical and retail activities.
For hearing care professionals and the broader industry, the transaction could have longer-term implications for hearing aid distribution, manufacturer-retailer relationships, and competition within the hearing healthcare market. However, the companies have not announced specific changes to product availability, professional partnerships, or clinical operations following the anticipated closing.
With the latest bond offering completed, Amplifon has taken another step toward finalizing the financial arrangements needed for the acquisition. Attention now turns to completing the remaining separation and closing requirements, with the transaction still expected to be finalized before the end of the year.
About Amplifon
Amplifon is a global hearing care retailer headquartered in Milan, Italy. The company operates approximately 9,700 locations across 24 countries on five continents and employs around 14,300 people worldwide.
With annual revenues of approximately €2.4 billion (~$2.76 billion USD), Amplifon provides hearing assessments, hearing aids, and related hearing care services through its international retail network.
Additional information is available through the Amplifon corporate website.
Source: Amplifon







